Leukogene Therapeutics is a preclinical-stage biopharmaceutical company focused on developing next-generation immunotherapies for the treatment of cancer. Leukogene's M2T™ platform is a novel, recombinant, high affinity Major Histocompatibility Complex Class II (MHCII) binding protein conjugated to tumor associated antigens. M2T™ functions as an antigen presenting cell (APC) engager that directly stimulates MHCII and generates a powerful T and B cell response against the chosen antigen. Leukogene's lead assets LTI-214 (M2T-CD33) for the treatment of hematological cancers (AML, MDS), and LTI-002 for solid tumors (pancreatic, ovarian and others) are currently in preclinical development. Leukogene expects to initiate first-in-human clinical evaluation of LTI-214 in AML in the near term.
